This mind-blowing study revealed how berberine lowers LDL cholesterol through a mechanism that’s completely different from ...

Coverage of a new PCSK9 trial makes bold claims about prevention and risk reduction. But how well do they hold up to scrutiny ...

Proprotein convertase subtilisin/kexin type-9 (PCSK9) is highly expressed in adult hepatocytes. PCSK9 binds to and promotes the degradation of the low-density lipoprotein (LDL) receptor, thereby ...

Patients receiving concomitant PCSK9 inhibitor therapy experienced greater LDL cholesterol reductions, exceeding 50% during ...

PITTSBURGH, Oct. 30, 2025 – An international team led by a University of Pittsburgh School of Medicine scientist has created a first-of-its-kind resource to identify those with a genetic risk for ...

Enlicitide is the first oral PCSK9 inhibitor to demonstrate statistically significant and clinically meaningful reductions in LDL-C compared to placebo in Phase 3 trials RAHWAY, N.J.--(BUSINESS WIRE)- ...

Patients with severe hypercholesterolemia who are unresponsive to a number of lipid-lowering therapies, including a PCSK9 inhibitor and high-dose statin, can have a significant reduction in ...

Please provide your email address to receive an email when new articles are posted on . Lerodalcibep further reduced LDL vs. placebo in well-treated patients with HeFH. More than 85% of the ...

High levels of low-density lipoprotein (LDL) cholesterol can cause artery blockages and diseases like heart attacks and strokes. Further, it raises the risk of cardiovascular disease (CVD). Thickened ...